Evidence map›Paper›PMID 39269218›Full record

ArticleInternational forum of allergy & rhinology2025

In office sampling of eosinophil peroxidase to diagnose eosinophilic chronic rhinosinusitis.

Jacquelyn K Callander, Annabelle R Charbit, Kritika Khanna, John V Fahy, Monica Tang, Maude Liegeois, Steven D Pletcher, Andrew N Goldberg, Jose G Gurrola, Andrew H Murr and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International forum of allergy & rhinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jacquelyn K CallanderDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.ORCID 0000-0002-7266-9868
Annabelle R CharbitCardiovascular Research Institute, University of California, San Francisco, California, USA.
Kritika KhannaCardiovascular Research Institute, University of California, San Francisco, California, USA.
John V FahyCardiovascular Research Institute, University of California, San Francisco, California, USA.
Monica TangDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, California, USA.
Maude LiegeoisCardiovascular Research Institute, University of California, San Francisco, California, USA.
Steven D PletcherDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.ORCID 0000-0003-0127-927X
Andrew N GoldbergDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Jose G GurrolaDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.ORCID 0000-0001-6801-5768
Andrew H MurrDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Anna ButrymowiczDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Patricia A LoftusDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.

Funding

Role of miRNAs in Th2-Driven inflammation in AsthmaP01HL107202 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 2012 to 2023
$23.3M
Protein carbohydrate interactions in the pathophysiology of asthma exacerbationsR01HL080414 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI John V Fahy · 2005 to 2026
$9.2M
Clinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0M
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and PhysiologyR01HL164787 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2022 to 2025
$2.6M
NHLBI NIH HHS P01 HL107202NHLBI NIH HHS R01 HL080414NHLBI NIH HHS R01 HL164787NHLBI NIH HHS U10 HL109146
6 · The paper itself

Abstract

backgroundPractical biomarkers for endotypic characterization of chronic rhinosinusitis (CRS) remain elusive, hindering clinical utility. Eosinophil peroxidase (EPX) is an enzyme released by activated eosinophils. The objective of this study was to evaluate a clinic EPX assay as a marker of eosinophilic CRS.

methodsSubjects with and without CRS presenting to a tertiary care rhinology clinic were prospectively enrolled, and nasal cytology brushings were collected from the middle meatus during in-clinic nasal endoscopy. ELISA assay was used to quantify EPX levels, and a customized multiplex immunoassay was used to quantify inflammatory cytokine mediators. Findings were correlated with clinical data.

resultsForty-two subjects were enrolled, including 31 CRS subjects and 11 controls. Median EPX levels were 125.0 ng/mL (standard deviation [SD] 1745.8) and 6.5 ng/mL (SD 99.0) for CRS group and controls, respectively (p = 0.003). EPX levels were associated with history of asthma (p = 0.015), allergies (p = 0.028), polyps (p = 0.0006), smell loss (p = 0.006), and systemic eosinophilia or elevated immunoglobulin E (p ≤ 0.0001). Twenty-eight subjects from both the CRS and control groups had prior pathology for comparison, with histologic confirmation of local tissue eosinophilia (>10 eosinophils/hpf) in 11 subjects. This subgroup had a median EPX level of 967.5 ng/mL compared to 10.6 ng/mL in 17 subjects without local tissue eosinophilia (p = 0.0008). EPX levels were positively correlated to interleukin-5 levels (p = 0.0005).

conclusionEPX levels can be measured via well-tolerated in-clinic collection of nasal mucus. EPX levels are associated with clinical markers of type 2 inflammation and tissue eosinophilia and may provide a valuable diagnostic tool to delineate eosinophilic CRS.

Indexed as

BiomarkersEosinophiliaEosinophil PeroxidaseRhinitisSinusitisAdultAgedChronic DiseaseCytokinesEosinophilsFemaleHumansMaleMiddle AgedProspective StudiesRhinosinusitisBiomarkersCytokinesEosinophil Peroxidasechronic rhinosinusitisendotypeeosinophil peroxidasenasal polyptype 2 inflammation

Identifiers

PMID39269218
PMCPMC11697230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.